Connor, Clark & Lunn Investment Management (CC&L)
NTLA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Intellia Therapeutics NTLA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.6M Buy
748,636
+488,927
+188% +$6.23M 0.02% 481
2025
Q4 		$2.33M Buy
+259,709
New +$3.58M 0.01% 886
2022
Q4 		– Sell
-160,356
Closed -$8.97M – 1365
2022
Q3 		$8.97M Buy
160,356
+131,876
+463% +$8.18M 0.06% 217
2022
Q2 		$1.47M Buy
28,480
+17,943
+170% +$911K 0.01% 533
2022
Q1 		$766K Buy
+10,537
New +$893K ﹤0.01% 712
2021
Q4 		– Sell
-61,732
Closed -$8.28M – 1164
2021
Q3 		$8.28M Sell
61,732
-4,380
-7% -$663K 0.04% 272
2021
Q2 		$10.7M Buy
66,112
+50,380
+320% +$3.92M 0.05% 239
2021
Q1 		$1.26M Buy
+15,732
New +$1.06M 0.01% 655

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return